TITLE:
      Alternate-Day Buprenorphine Administration. Phase VII - 8
SUMMARY:
      The purpose of this study is to determine if four times a subjects daily maintenance dose
      will hold for 96 hours without changes in agonist and antagonist effects under open dosing
      conditions.
ELIGIBILITY CRITERIA:
      Please contact site for information.
